

Substitute Form PTO-1449 (Modified) Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 06275-0512US1	Application No. 10/580,589
	Applicant Philippe Rogueda		
	Filing Date May 25, 2006	Group Art Unit 1616	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	4,579,854	04/01/86	Iwakuma et al.			
	2						
	3						
	4						
	5						

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	6	DE 4129535	03/12/93	Germany				
	7	DE 10205087	08/21/03	Germany				
	8	WO02/12265	02/14/02	WIPO				
	9	WO02/12266	02/14/02	WIPO				
	10	WO02/88167	10/03/02	WIPO				
	11	WO02/76933	11/07/02	WIPO				
	12	WO03/066031	08/14/03	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	13	Steckel, H. et al., "A Novel Formulation Technique for metered Dose Inhaler (MDI) Suspensions", International Journal of Pharmaceutics, Amsterdam, NL, Vol. 284, No. 1-2, (2004), pp. 75-82.
	14	Williams III, R.O. et al., "Influence of Formulation Technique for Hydroxypropyl-Beta-Cyclodextrin on the Stability of Aspirin in HFA 134a", European Journal of Pharmaceutics and Biopharmaceutics, Elsevier Science Publishers B.V., Amsterdam, NL, Vol. 47, No. 2, (1999), pp. 145-152.
	15	
	16	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	